source
- China’s five-year plan positions it to become a global leader in innovative biopharma by 2030China’s latest five‑year plan sets an ambitious target to turn the country into a major source of innovative medicines for the world market. Experts cited by BioSpace say the goal is within reach,…
- US biotech faces growth slowdown as China’s coordinated investment threatens industryDuring a BioSpace webinar, industry experts warned that uncertainty in U.S. policy is slowing biotech growth while China accelerates its life-science sector with deliberate investment. Strand Ther…